ImmunityBio, Inc. revenue for the last year amounted to 14.74 M USD, the most of which — 14.74 M USD — came from its highest performing source at the moment, Immunotherapies, the year earlier bringing 622.00 k USD. The greatest contribution to the revenue figure was made by United States — last year it brought ImmunityBio, Inc. 14.21 M USD, and the year before that — 31.00 k USD.